North China Pharmaceutical Company.Ltd (SHA:600812)
China · Delayed Price · Currency is CNY 5.14
+0.08 (1.58%)
Aug 20, 2026, 3:00 PM CST
SHA:600812 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,385 | 1,541 | 1,660 | 988.28 | 1,683 | 5,305 |
Cash & Short-Term Investments | 1,385 | 1,541 | 1,660 | 988.28 | 1,683 | 5,305 |
Cash Growth | -30.63% | -7.16% | 68.00% | -41.27% | -68.28% | 8.10% |
Accounts Receivable | 2,863 | 2,595 | 2,292 | 2,066 | 2,426 | 2,046 |
Other Receivables | 1,395 | 1,443 | 1,499 | 1,953 | 1,934 | 2,620 |
Receivables | 4,259 | 4,038 | 3,791 | 4,019 | 4,360 | 4,667 |
Inventory | 2,413 | 2,411 | 2,511 | 2,608 | 2,523 | 2,392 |
Other Current Assets | 208.5 | 141.37 | 297.44 | 402.34 | 416.92 | 348.74 |
Total Current Assets | 8,265 | 8,131 | 8,259 | 8,018 | 8,983 | 12,712 |
Property, Plant & Equipment | 6,740 | 6,880 | 7,203 | 7,473 | 7,869 | 8,251 |
Long-Term Investments | 1,267 | 1,252 | 1,205 | 1,220 | 917.98 | 875.9 |
Goodwill | - | - | - | 3.34 | 3.34 | 3.34 |
Other Intangible Assets | 2,988 | 3,024 | 2,756 | 1,975 | 1,650 | 1,344 |
Long-Term Deferred Tax Assets | 50.89 | 49.15 | 72.43 | 52.11 | 50.27 | 45.03 |
Long-Term Deferred Charges | 2,141 | 2,055 | 1,918 | 2,157 | 1,688 | 1,639 |
Other Long-Term Assets | - | - | 58.55 | 58.55 | 58.7 | 58.83 |
Total Assets | 21,452 | 21,392 | 21,471 | 20,957 | 21,221 | 24,930 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2,430 | 2,451 | 2,295 | 2,490 | 2,783 | 2,891 |
Accrued Expenses | 191.79 | 206.01 | 202.93 | 200.38 | 238.11 | 299.84 |
Short-Term Debt | 6,366 | 6,242 | 7,095 | 5,468 | 5,276 | 7,627 |
Current Portion of Long-Term Debt | 1,894 | 2,915 | 448.19 | 1,037 | 2,930 | 2,323 |
Current Portion of Leases | - | 56.69 | 184.3 | 262.95 | 300.15 | 199.12 |
Current Income Taxes Payable | 63.32 | 35.06 | 16.02 | 34.58 | 46.42 | 37.27 |
Current Unearned Revenue | 164.98 | 161.48 | 281.75 | 313.25 | 295.87 | 257.75 |
Other Current Liabilities | 326.57 | 331.56 | 438.25 | 462.89 | 540.12 | 604.85 |
Total Current Liabilities | 11,437 | 12,399 | 10,962 | 10,269 | 12,409 | 14,240 |
Long-Term Debt | 2,852 | 1,877 | 3,459 | 4,081 | 2,129 | 3,301 |
Long-Term Leases | 124.53 | 124.43 | 263.53 | 299.16 | 413.39 | 326.74 |
Long-Term Unearned Revenue | 88.37 | 89.8 | 74.02 | 36.81 | 40.06 | 44.44 |
Long-Term Deferred Tax Liabilities | 0.55 | 0.55 | 29.1 | - | - | - |
Other Long-Term Liabilities | 16.18 | 16.18 | 9.74 | 0.9 | 0.9 | 0.9 |
Total Liabilities | 14,518 | 14,507 | 14,797 | 14,686 | 14,993 | 17,913 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1,716 | 1,716 | 1,716 | 1,716 | 1,716 | 1,716 |
Additional Paid-In Capital | 3,870 | 3,870 | 3,862 | 3,899 | 3,886 | 3,886 |
Retained Earnings | -29.71 | -65.19 | -196.77 | -306.61 | -311.5 | 480.68 |
Comprehensive Income & Other | -6.01 | -5.51 | 8.26 | 7.04 | 9.5 | 2.94 |
Total Common Equity | 5,550 | 5,515 | 5,389 | 5,315 | 5,300 | 6,085 |
Minority Interest | 1,384 | 1,370 | 1,285 | 955.11 | 928.25 | 931.75 |
Shareholders' Equity | 6,934 | 6,885 | 6,675 | 6,270 | 6,228 | 7,017 |
Total Liabilities & Equity | 21,452 | 21,392 | 21,471 | 20,957 | 21,221 | 24,930 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 11,237 | 11,215 | 11,450 | 11,148 | 11,049 | 13,777 |
Net Cash (Debt) | -9,852 | -9,674 | -9,790 | -10,159 | -9,366 | -8,472 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -5.76 | -5.65 | -5.70 | -6.23 | -5.46 | -4.98 |
Filing Date Shares Outstanding | 1,716 | 1,716 | 1,716 | 1,716 | 1,716 | 1,716 |
Total Common Shares Outstanding | 1,716 | 1,716 | 1,716 | 1,716 | 1,716 | 1,716 |
Working Capital | -3,171 | -4,268 | -2,702 | -2,251 | -3,426 | -1,528 |
Book Value Per Share | 3.23 | 3.21 | 3.14 | 3.10 | 3.09 | 3.55 |
Tangible Book Value | 2,562 | 2,490 | 2,633 | 3,337 | 3,646 | 4,738 |
Tangible Book Value Per Share | 1.49 | 1.45 | 1.53 | 1.95 | 2.13 | 2.76 |
Buildings | - | 4,536 | 4,405 | 4,357 | 4,282 | 4,011 |
Machinery | - | 8,667 | 7,547 | 6,804 | 6,744 | 6,416 |
Construction In Progress | - | 259.6 | 381.14 | 162.35 | 154.67 | 672.47 |